We confirmed this in current analysis, as the ICER was $69182.50 in advanced NSCLC patients with a high TMB, irrespective of their tumor PD-L1 expression levels, which was lower than the values of ICER in three PD-L1 expression populations (≥50, ≥1, and <1%). This evidence concerns the gene CD274 and neoplasm.